An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy

NCT07631871 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Neoplasms
Solid Tumors
HER2 Positive Solid Tumor
Endometrial Neoplasm
Urothelial Carcinoma (UC)
Pancreatic Neoplasms
Colorectal Neoplasms
Head and Neck Neoplasms
Cervical Neoplasms
Ovarian Neoplasms

Interventions

DRUG: Zanidatamab

Sponsor

Haihua Yuan